



A NOVEL PDE1A COUPLED TO M2AChR AT PLASMA MEMBRANES FROM BOVINE TRACHEAL SMOOTH MUSCLE

Journal:	<i>Journal of Receptors and Signal Transduction</i>
Manuscript ID:	Draft
Manuscript Type:	Original Paper
Date Submitted by the Author:	n/a
Complete List of Authors:	Mastromatteo, Patrizia; IME-UCV, Biomembranes Placeres, Fabiola; IME-UCV, Biomembranes Alfonzo-González, Marcelo; IME-UCV, Biomembranes Alfonzo, Ramona; IME-UCV, Biomembranes Becemberg, Itala; IME-UCV, Biomembranes Alfonzo, Marcelo; IME-UCV, Biomembranes
Keywords:	Muscarinic antagonists, m2AChR, airway smooth muscle, asthma

SCHOLARONE™
Manuscripts

Title page:**A NOVEL PDE1A COUPLED TO M₂AChR AT PLASMA MEMBRANES FROM BOVINE TRACHEAL SMOOTH MUSCLE.**

Authors: Patrizia Mastromatteo-Alberga, Fabiola Placeres-Uray, Marcelo A. Alfonso-González, Ramona Gonzalez de Alfonso, Itala Lippo de Becemberg, and Marcelo J. Alfonso. Sección de Biomembranas. Instituto de Medicina Experimental. Facultad de Medicina. Universidad Central de Venezuela. Sabana Grande 50587. Caracas. Venezuela.

Corresponding author: Marcelo J. Alfonso. Sección de Biomembranas. Instituto de Medicina Experimental. Facultad de Medicina. Universidad Central de Venezuela. Sabana Grande 50587. Email: hmag5@hotmail.com

Key Words: Muscarinic antagonists, m₂AChR, airway smooth muscle, asthma.

ABSTRACT.

Muscarinic antagonists, via muscarinic receptors increase the cAMP/cGMP levels at bovine tracheal smooth muscle (BTSM) through the inhibition of phosphodiesterases (PDEs), displaying a similar behavior of vinpocetine (a specific-PDE1 inhibitor). The presence of PDE1 hydrolyzing both cyclic nucleotides in BTSM strips was revealed. Moreover, a vinpocetine and muscarinic antagonists inhibited PDE1 located at plasma membranes (PM) fractions from BTSM showing such inhibition, an M_2AChR pharmacological profile. Therefore, a novel Ca^{2+}/CaM dependent and vinpocetine inhibited PDE1 was purified and characterized at PM fractions from BTSM. This PDE1 activity was removed from PM fractions using a hypotonic buffer and purified some 38 fold using two columns (Q-Sepharose and CaM-agarose). This PDE1 was stimulated by CaM and inhibited by vinpocetine showing two bands in PAGE-SDS (56, 58 kDa) being the 58 kDa identified as PDE1A by Western blots. This PDE1A activity was assayed with [3H]cGMP and [3H]cAMP exhibiting a higher affinity as K_m (μM) for cGMP than cAMP but being close values with V_{max} cAMP/cGMP ratio of 1.5. The co-factor Mg^{2+} showed similar $K_{(A)}$ (mM) for both cyclic nucleotides. Vinpocetine showed similar inhibition concentration 50% (IC_{50} of 4.9 and 4.6 μM) for cAMP and cGMP respectively. CaM stimulated the cyclic nucleotides hydrolysis by PDE1A exhibiting similar activation constant as $K_{(CaM)}$, in nM range. The original finding was the identification and purification of a vinpocetine and muscarinic antagonist-inhibited and CaM-activated PM-bound PDE1A, linked to M_2AChR . A model of this novel signal transducing cascade for the regulation of cyclic nucleotides levels at BTSM is proposed.

Main Text:**INTRODUCTION.**

Muscarinic activation of Airway smooth muscle (ASM) is relevant in the bronchoconstriction presents in asthma (1-3). Acetylcholine acting on muscarinic receptors (MACHRs) at the ASM sarcolemma stimulate signal transducing cascades to activate the ASM machinery (3,4). The MACHRs belong to the GPCR family linked to intracellular specific effectors (5,6). Mammalian MACHRs (m_1 - m_5) have been described (6) and ASM expresses both m_2 and m_3 AChRs (7). ASM has a mixed population of M_2 and M_3 AChRs (8) being the M_2 AChRs more abundant at plasma membranes (PM) fractions from ASM (9,10). MACHRs are involved in the rise/decline of cAMP/cGMP levels in ASM. Thus, atropine (a non-selective muscarinic antagonist), significantly increased the cGMP and cAMP levels at bovine tracheal smooth muscle (BTSM) being this effect similar to the ones produced by vinpocetine, a specific PDE1 inhibitor (11). Consequently, muscarinic antagonists and vinpocetine effects may be the result of the PDE1 inhibition (12). Tracheal smooth muscle (TSM) exhibits Ca^{2+} /CaM dependent PDE1s (CaM-PDE) that hydrolyze cAMP and cGMP with equal capacity (13-15). CaM-PDEs are mediators between the Ca^{2+} and cyclic nucleotides second messenger allowing cyclic nucleotide-dependent processes to be regulated by $[Ca^{2+}]_i$ (16). PDE1 family has three genes (PDE1A, PDE1B, and PDE1C) (17).

In this work, the functional presence of PDE1 at BTSM strips was demonstrated. Moreover, a PM-bound PDE1 was purified, characterized as a vinpocetine-inhibited and CaM-stimulated PDE activity with MW of 58 kDa and identified by Western blotting as PDE1A. Moreover, a novel signal-transducing cascade linking an M_2 AChR to this membrane-bound PDE1A is proposed.

METHODS.

The compounds from Sigma-Aldrich (USA): Trizma Base, PMSF, DTT, sucrose, benzamidine, EGTA, EDTA, cAMP, cGMP, Q-sepharose, CaM-agarose, HEPES, atropine, 4-DAMP, vinpocetine and snake venom 5' nucleotidase. Kits for cGMP determination (TRK-500) and ECL Western Blotting Reagent Pack from GE/Healthcare, Life Sciences. Kits for cAMP Radioassay determination (KAPH2-172) from Diagnostic Products Corporation (USA). Cyclic [8,5-³H] GMP (25-50 Ci/mmol) and cyclic [5',8-³H] AMP (30-60 Ci/mmol), from Perkin Elmer (USA). Reagents for SDS-PAGE and protein (Mw) standards, Dowex-1-X-8 (chloride form) and Precision Plus protein™ Western C™ Pack from BIORAD (USA). Other chemicals pro-analysis grade from E. Merck and Fisher. The recombinant CaM was produced using bacteria *E. coli* strain BL21 (DE3) pLysS transformed with plasmid pETCM under the control of a T7 promoter. Antibodies from Santa Cruz Biotechnology, as polyclonal IgG: human origin PDE1A, polyclonal IgG of PDE1B of human origin and Polyclonal IgG of PDE1C of human origin.

Preparation and incubation of Bovine TSM strips.

Bovine tracheas obtained from a local slaughterhouse were processed as described (18). To evaluate the cAMP/cGMP content, BTSM strips were placed into a specially designed multi-organ chamber (400 mL) with 95% O₂ and 5% CO₂, holding simultaneously several BTSM strips at 37°C, at 1 g of tension. BTSM strips were removed at specific times and placed into liquid nitrogen.

Measurement of Cyclic Nucleotides in Bovine TSM strips.

Frozen BTSM strips were homogenized in 5% TCA (18). TCA extractions were performed twice, and the insoluble material was removed by centrifugation at 1,500xg for 10 min at 4°C, which was processed for protein determination and the acid

1
2
3 supernatants were combined, extracted twice with ether to remove TCA, frozen at –
4
5 80°C and lyophilized (18). The acid-soluble nucleotide extract was dissolved in a
6
7 small volume of 50 mM Tris-HCl, 4 mM EDTA, pH 7.4, and kept frozen at -80°C.
8
9
10 The cyclic nucleotide recovery was between 95 and 98% for both nucleotides. Cyclic
11
12 GMP was determined using a radioimmunoassay with a commercial kit (TRK-500)
13
14 (19). Cyclic AMP was determined using a radioassay kit (KAPH2-172) as described
15
16 (20).
17

18 **Subcellular fractionation and plasma membranes preparation from BTSM.**

19
20 The subcellular fractionation of BTSM and the isolation of the plasma membrane
21
22 fractions (PM) were performed as described (20). This procedure was slighted
23
24 modified to improve the yield of PM fraction. Thus, in the original procedure, there is
25
26 a discontinuous sucrose gradient assembled by the 0.3 M/0.82 M/1.28 M sucrose
27
28 solutions. The 0.82 M sucrose was removed and the PM fraction was collected at
29
30 0.3M/1.28 sucrose interphase.
31
32

33 **The extraction of vinpocetine-inhibited and CaM-stimulated PDEs from plasma** 34 35 **membrane fractions.**

36
37 PDE1 was extracted from PM-BTSM using a method described for membrane-bound
38
39 retinal PDE6 (21). The PM fraction was incubated with a hypotonic buffer (10 mM
40
41 HEPES; pH 7.0; 0.1 mM EDTA; 1 mM DTT; 0.25 mM PMSF) on ice under agitation
42
43 for 15 min and centrifuged at 150,000xg for 15 min. This extraction procedure was
44
45 performed 6 times. All supernatants were pooled as the hypotonic extract (HE),
46
47 concentrated under low speed centrifugation using Millipore YM-10 to 1-2 mL and
48
49 the sediment (SED) was discarded.
50
51
52
53
54
55
56
57
58
59
60

The purification of vinpocetine-inhibited and CaM-stimulated PDE1 activity.

The vinpocetine-inhibited and CaM-stimulated PDE1 activity was purified at 4°C (22). Thus, an ion exchange chromatography (Q-sepharose) followed by CaM-agarose. The Q-sepharose (1 x 5 cm) column was equilibrated with Buffer 1 (20 mM Tris-HCl; 1 mM imidazole, 0.1 mM EGTA, 1 mM magnesium acetate) at pH 7.0 plus 5 mM DTT. Subsequently, HE was applied to Q-sepharose column, washed with 20 mL Buffer 1 containing 50 mM NaCl. Finally, the Q-column was eluted using a linear gradient of NaCl (0.4-1.0 M). Protein fractions (Pool I) and the vinpocetine inhibited and CaM activated PDE were evaluated.

CaM-agarose (5 mL) was washed with Buffer 1 containing 2 M Guanidine hydrochloride (23). This CaM-agarose was equilibrated with Buffer 1 containing 100 µM CaCl₂ and 5 mM DTT. Subsequently, "Pool I" was mixed with CaM-agarose and incubated overnight. The next day, the slurry was packed into a column and washed with Buffer 1. Later, CaM-agarose column eluted with Buffer 1 containing 2 mM EGTA. Protein fractions (Pool II), concentrated to 0.5-1 ml using low speed centrifugation with Millipore YM-10 and 30% ethylene glycol was added and kept at -80°C. The vinpocetine inhibited and CaM activated PDE were evaluated in Pool II.

Cyclic nucleotide phosphodiesterase (PDE) activities.

The PDE were assayed using [³H]cGMP and [³H]cAMP (12). Briefly, protein (10-50 µg) were incubated for 15 min at 30°C with (0.1 µC/assay) of either 2,8 [³H]cAMP or 8-[³H]cGMP in a buffer containing 0.3 mM of cAMP or cGMP, 40 mM Tris-HCl pH 7.5, 10 mM MgCl₂ and 1 unit of snake venom 5' nucleotidase. Reactions were stopped with 10 mM EDTA and transfer to 4°C. Later, samples were applied to anion exchange (AG-1-X8, Cl⁻ form, 200-400 mesh) (2ml) columns and the non-charged products ([³H]guanosine or [³H]adenosine) eluted with 50% ethanol and transferred to

1
2
3 vials containing Aquasol®. The [³H] was counted with 30% efficiency in RackBeta
4
5 LKB, Wallac 1214/1219.
6

7 **SDS-PAGE analysis and Immunodetection of PDE isoenzymes by Western blots:**

8
9 PM polypeptides were separated on SDS-PAGE 10 % (24). For the Western blots,
10 these SDS-PAGE gels were transferred to PDVF (25). Protein Blots were blocked for
11 2-4 hours at 4°C in PBS-2 % BSA-0.05 % (v/v) Tween 20. After washing twice with
12 PBS-Tween, the PDVF membrane was incubated for 4-6 hours at 4° with (1/1000)
13 polyclonal IgG specific for PDE1 (A, B, C). Then, the PDVF membrane was washed
14 overnight with PBS-Tween 20 and incubated for 4-6 hours at 4°C with (1/1000) HRP
15 anti rabbit IgG. To identify the immunoreactivity proteins (positive bands), a
16 Precision Plus protein™ Western C™ Pack and ECL Western Blotting Reagent Pack
17 were employed.
18
19
20
21
22
23
24
25
26
27
28
29

30 **Other procedures and methods:** Protein was quantified using BSA as standard as
31 described (26). The enzyme kinetic parameters were estimated using the program
32 GraphPad Prism (version 6), which requires at least three different experimental data,
33 to obtain the kinetic enzyme parameters (*K_m*, *V_{max}*). The statistical significance was
34 estimated using student *t*-test.
35
36
37
38
39

40 **RESULTS.**

41 **An active PDE1 is revealed in intact BTSM strips.**

42
43 The existence of an active dual PDE1 in BTSM was established. BTSM strips were
44 exposed to atropine for 15 min to raise the cAMP/cGMP levels (12). Later, they were
45 contracted using a classic KCl (60 mM) depolarizing procedure (27) and the cAMP
46 and cGMP content was determined. Figure 1 shows the cAMP amounts at “0T” was
47 26.1 ± 1.6 pmoles/mg protein, which sharply decreased to 6.0 ± 0.7 pmoles/mg
48 protein at 20s, which is similar to the cAMP level in unstimulated strips. Identical
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 behavior was found for the cGMP levels decreasing from “0T” of 12.6 ± 1.5
4 pmoles/mg protein to basal values of 2.0 ± 0.4 pmoles/mg protein at 20s, after KCl
5 exposure.
6
7
8

9 **Subcellular localization of vinpocetine-inhibited PDE1 (ViPDE) at BTSM.**

10 Muscarinic antagonist and vinpocetine inhibited PDE1 (ViPDE1) are located in
11 particulate fractions of BTSM (12). The atropine sensitive PDE was useless because
12 this activity has poor reproducible but the ViPDE1 exhibited good reproducibility and
13 reliable activity. Thus, BTSM subcellular fractionation (20,28) was employed to
14 locate this ViPDE1. These fractions are: Crude extract: E, Nuclear fraction: N,
15 Mitochondrial fraction: M, microsomal fraction: P and soluble or cytosol fraction: S.
16 Moreover, a modification to generate the PM fraction from BTSM at the 0.3/1.28 M
17 sucrose interface was done. All subcellular fractions were assayed using cAMP and
18 cGMP. Table 1 showed that the crude M and P fractions displayed greater enzyme
19 activities than the N fraction and fraction S. Moreover, the greater specific activity
20 for both cAMP and cGMP was found at PM fraction in comparison to other
21 subcellular fractions. These results indicated that the ViPDE1 is associated with the
22 PM fractions.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **Muscarinic M₂AChR regulate the PM-bound ViPDE1.**

41 PM fractions from BTSM exhibit high concentrations of M₂AChR subtype (10).
42 Thus, classic M₃AChR muscarinic antagonist, such as 4-DAMP and methoctramine
43 as an M₂AChR selective antagonists were assayed. In Figure 2, methoctramine was
44 more potent than 4-DAMP to inhibit this PM-bound-PDE1 showing methoctramine,
45 an IC₅₀ = -8.12 ± 0.21 and 4-DAMP, an IC₅₀ = -6.68 ± 0.13 . These results suggest that
46 a pharmacological profile of an M₂AChR (10) is responsible of PDE1 inhibition.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Extraction of ViPDE1 from PM fractions.

Membrane proteins as PDE1 can be extracted/solubilized using procedures such as high/low ionic strength treatments or detergents. Initially, low/high ionic buffers were tested and the low ionic strength buffer was the best procedure to remove most of the ViPDE. Thus, the ViPDE was removed using a similar procedure for the extraction of membrane-bound cGMP-PDE6 from the bovine retinal cones (21). Thus, a hypotonic buffer containing 10 mM HEPES, 0.1 mM EDTA, 1 mM DTT and 0.25 mM PMSF at pH 7.5 was employed. Table 2 indicates that most of the ViPDE was at the hypotonic extract (HE), whereas, a low ViPDE was at the sediment remnants (SED) and the atropine sensitive PDE was absent in the HE fraction. This was the reason that the vinpocetine inhibition (ViPDE) activity was the main tool for the PDE1 purification.

Purification of the ViPDE using Q-sepharose and CaM-agarose columns.

The ViPDE1 activity was purified as described (22) and modified: The EH was applied to Q-sepharose column, equilibrated with buffer 1. Later, the Q-sepharose was washed with of buffer 1 containing 50 mM NaCl. Finally, the Q-sepharose was eluted with a linear gradient of NaCl (0.4-1.0 M) as shown in Figure 3A. "Pool I" protein was concentrated to 1.0 to 2.0 mL using a Millipore YM-10. In the inset of Figure 3A shows that PDE1 was inhibited in about 70% by vinpocetine (20 μ M vinpocetine), while CaM (5 nM) increased in more than 80% this PDE1.

Purification of the ViPDE1 using a CaM affinity column.

PDE1 possess two CaM binding sites, which allowed the purification of this PDE1 using a CaM agarose. This affinity column was washed with 2M Guanidine-HCl and equilibrated with Buffer 1 containing 100 μ M Ca^{2+} and 5 mM DTT. Subsequently, "Pool I" was mixed with CaM agarose and incubated overnight at 4°C. The next day, the column was packed and washed with Buffer 1 (without Ca^{2+} or EGTA), eluted

1
2
3 with Buffer 1 containing 2 mM EGTA as shown in Figure 3B. Protein fractions as
4
5 “Pool II” were concentrated using a Millipore YM-10, up to 1-2 mL and, ethylene
6
7 glycol was added 30% and stored at -80°C. In the inset of Figure 3B shows that
8
9 vinpocetine (20 μ M) inhibited significantly in 70%. However, CaM (5 nM) increased
10
11 at more than double (116%) of PDE.

12
13
14 A summary of the purification of the ViPDE1 is shown in Table 3. E fraction showed
15
16 a specific activity of 4.0 ± 0.2 pmoles/min/mg protein to the Pool II from CaM-
17
18 agarose with of 152 ± 8 pmoles/min/mg protein, rendering a purification around 38
19
20 times. PDE1 activity in “Pool I” exhibits specific activity of 72 ± 6 pmoles/min/mg
21
22 protein, being some 18 times of purification, which was the enzyme sample used to
23
24 perform the kinetic enzyme characterization.
25
26

27
28 **Determination of K_m and V_{max} for cAMP and cGMP, the $K_{(A)}$ for Mg^{2+} , the**
29
30 **$K_{(CaM)}$ for CaM and IC_{50} for vinpocetine of the ViPDE1.**
31

32
33 The kinetic parameters were determined using the partially purified PDE1 presents in
34
35 “Pool I”, being more stable activity and abundant protein. Initially, the proportionality
36
37 between the protein concentration and PDE1 activity was established being linear to
38
39 50 μ g protein. Figure 4A shows the kinetic behavior in the presence of cAMP/cGMP
40
41 on the PDE1. Thus, both cyclic nucleotides increased the PDE1 activity, in a
42
43 concentration dependent manner, reaching saturation at 20 μ M or greater for both
44
45 nucleotides. The K_m for cAMP (8.4 ± 0.7 μ M) vs K_m for cGMP (6.1 ± 1.5 μ M)
46
47 showing more affinity for cGMP. Additionally, the V_{max} for cAMP (99 ± 3
48
49 pmoles/min/mg protein) was significantly higher ($p < 0.05$) than V_{max} for cGMP (66
50
51 ± 5 pmoles/min/mg of protein) displaying a cAMP/cGMP V_{max} ratio of 1.5.
52
53

54
55 The Mg^{2+} dependency of the PDE1, in presence of cAMP and cGMP was studied.
56
57 Figure 4B shows that increasing concentrations of Mg^{2+} augmented the PDE1 activity
58
59
60

1
2
3 reaching maximal response at 1 mM Mg^{2+} for both cyclic nucleotides. Likewise, the
4
5 $K_{(A)}$ for Mg^{2+} were determined in the presence of cAMP (0.32 ± 0.02 mM) and in the
6
7 presence of cGMP a $K_{(A)}$ of 0.24 ± 0.01 mM. These $K_{(A)}$ parameters exhibited close
8
9 values for both cyclic nucleotides. The inhibitory effect of vinpocetine was evaluated
10
11 in Figure 5A, increasing amounts of this inhibitor decreased PDE1. Thus, the $IC_{50} =$
12
13 4.9 ± 0.2 μ M for vinpocetine in the presence of the cAMP and an $IC_{50} = 4.6 \pm 0.3$ μ M
14
15 with cGMP were estimated. Thus, a similar kinetic behavior towards vinpocetine,
16
17 independently of the cyclic nucleotides was observed. A classic biochemical property
18
19 of the PDE1 family is the CaM stimulation. Figure 5B showed an increment of PDE1
20
21 activity as CaM increased, reaching a maximal response at 5 nM CaM. Accordingly,
22
23 the CaM concentration required for half-maximal activation ($K_{(CaM)}$); in the presence
24
25 of the cAMP was 2.0 ± 0.5 nM, while with cGMP was 1.6 ± 0.3 nM. These data
26
27 indicate similar CaM activation being independent of cyclic nucleotides used.
28
29
30
31

32 **SDS-PAGE analysis of the ViPDE active fractions.**

33
34 SDS-PAGE 10% was performed as shown in Figure 6. Thus, the PM fraction, (lane 1)
35
36 and HE, (lane 2), displayed similar dense membrane polypeptides pattern. The Pool I
37
38 from Q-sepharose (lane 3), the protein bands decreased significantly to a define
39
40 pattern. Finally, CaM-agarose (lane 4) renders a greatest purification showing two
41
42 relevant bands of 56 and 58 kDa. An Mw protein standard from 28.3 to 132 kDa is
43
44 shown in line 5.
45
46
47

48 **Identification of PDE1A by Western-blotting analysis.**

49
50 Western-blotts using specific antibodies against PDE1A, PDE1B and PDE1C
51
52 isoforms were employed to identify this Vi-PDE1. SDS-PAGE 10% gels were
53
54 transferred to the PDVF membranes being exposed to the antibodies against the three
55
56 PDE1 isozymes. It can be seen in lower inset of Figure 6 that the anti-PDE1A
57
58
59
60

1
2
3 antibodies detected a signal corresponding to a band, which migrated at $MW_{app} \approx 58$
4 kDa in all samples analyzed, i.e., PM, HE, Pool I and Pool II fractions. The PDE1B
5 and PDE1C antibodies were negative on the PDVF membranes. These Western blots
6 demonstrated that a PDE1A is located at PM from BTSM.
7
8
9
10

11 12 13 **DISCUSSION.**

14 Muscarinic antagonists and vinpocetine (PDE1 inhibitor) increased simultaneously
15 both cAMP and cGMP levels in BTSM, via the inhibition of PDE1 (12). Several
16 topics were addressed: 1) The demonstration of an active PDE1 in intact BTSM. 2)
17 The subcellular location of a ViPDE1. 3) The muscarinic receptor subtype involves in
18 this muscarinic antagonist inhibition. 4) The isolation and purification of this
19 membrane-bound ViPDE1. 5) The identification of this ViPDE1 as a PDE1A using
20 Western-blots. 6) The kinetic enzymatic characterization of this PDE1A.
21
22
23
24
25
26
27
28
29

30 Atropine raises the cyclic nucleotides content in BSTM strips (12), which were
31 contracted using the KCl depolarizing procedure (27), inducing at 20s, a dramatic fall
32 in the cyclic nucleotides content at BTSM strips. This decline in both cyclic
33 nucleotides levels may be a result of CaM-PDE1 activation, via KCl induces
34 membrane depolarization and initiates a Ca^{2+} influx, through the opening of L-type
35 Ca^{2+} channels located at BTSM sarcolemma increasing the $[Ca^{2+}]_i$ and the active CaM
36 levels (27) inducing the activation of the BTSM contraction machinery (29) and the
37 PDE1s (22,30). The existence of an active PDE1 enzyme in intact BTSM was
38 demonstrated.
39
40
41
42
43
44
45
46
47
48
49

50 The muscarinic antagonist inhibited and ViPDE1 activity was present at particulate
51 fractions from the BTSM (12). Thus, ViPDE1 was more active in the presence of
52 cAMP than cGMP and detected in particulate fractions such as Nuclear (N),
53
54
55
56
57
58
59
60

1
2
3 Mitochondrial (M) and Microsomal (P) fractions with little activity at cytosol (S)
4
5 fraction. Moreover, the PM fractions displayed the highest specific PDE activity.
6

7
8 This PDE1 was inhibited by muscarinic antagonists acting on M₂AChRs at the
9
10 sarcolemma from BTSM (10,20,28). Thus, methoctramine (M₂AChR selective
11
12 antagonist) (31) was more effective than 4-DAMP (a M₃AChR selective antagonist)
13
14 (32) inhibiting this membrane-bound PDE1A. This pharmacological profile belongs
15
16 to an M₂AChR (10). ASM displays a mixed population of M₂ and M₃ subtypes (8)
17
18 being the M₂ subtype, the most abundant at PM-BTSM (10). M₂AChRs participate
19
20 directly in ASM contraction via Gi/o proteins (18,33-37). However, our experimental
21
22 data provided by the muscarinic antagonists inhibition of ViPDE1A at PM-BTSM,
23
24 took place in the absence of GTP or analogs, suggesting a direct coupling mechanism
25
26 between M₂AChR and ViPDE1A. In this sense, a direct coupling mechanism has
27
28 been demonstrated for other GPCR as a direct interaction between the M₃AChR, and
29
30 its effector enzyme, PLC β3 (38).
31
32

33
34 The muscarinic antagonist inhibition was lost as this PDE1 was removed from the PM
35
36 because the M₂AChRs remained at the sediment. Consequently; the PDE1
37
38 purification was followed using the ViPDE1 activity. This PDE1A from PM-BTSM
39
40 was extracted using a hypotonic buffer, as described for the isolation of the
41
42 membrane-bound PDE6 (21). PDE6 is heteromeric protein (39) and plays role in
43
44 visual signal transduction by regulating cGMP levels (21,40). Furthermore, PDE6s
45
46 anchor to the membranes since the catalytic subunits PDE6α and PDE6β, are post-
47
48 translationally farnesylated and geranylgeranylated, respectively (41). Other PDE1
49
50 activities have identified in spermatozoa, associated with the PM (50%–60%) (42).
51
52 This membrane-PDE1A activity is solubilized using Triton X-100, which was not
53
54 stimulated by CaM because CaM is tightly bound to this PDE1A (43). These
55
56
57
58
59
60

1
2
3 biochemical properties of PDE1A from spermatozoa are distinctive of the PDE1A
4
5 here described.

6
7 The PDE1s catalyze the degradation of cAMP and cGMP to their 5'AMP and 5'GMP
8
9 and constitute a large family (44,45), with three PDE1A, B and C genes (46), which
10
11 in turn give rise to multiple isoforms by alternative "splicing" of mRNA (17,47-49),
12
13 differing in their ends (C-and N-terminal) sequence. The family of the PDE1s has a
14
15 similar structure divided into three domains: A regulatory containing two CaM-
16
17 binding domains located at the N-terminal end and a conserved catalytic domain and
18
19 dimerization motif at C-terminal (17,46,50,51). The PDE1 isoform here characterized
20
21 was identified by Western blots using specific polyclonal antibodies against the
22
23 PDE1A, PDE1B and PDE1C. Only a positive band for PDE1A with a 58 kDa was
24
25 found from the PM, HE, Pool I and Pool II fractions. Other antibodies against the
26
27 PDE1B and PDE1C isoforms were negative. After, the CaM-agarose column, the
28
29 presence of doublet relevant bands of 56-58 kDa in SDS-PAGE was observed. The
30
31 58-kDa band is PDE1A while the 56-kDa band could be protein-partner similar to that
32
33 previously identified in rat spermatozoa as a CaM binding protein with still unknown
34
35 function (52).
36
37
38
39

40 The affinity for cGMP of this PDE1A was slightly higher than cAMP. This selectivity
41
42 for cGMP being lower for the cAMP has been described for PDE1A and PDE1B (50).
43
44 This PDE1A is different to the PDE1C, which hydrolyzes both cyclic nucleotides
45
46 with similar high affinity (50).
47
48

49 PDEs require Mg^{2+} for activity. This PDE1A exhibited a classic Michaelis-Menten
50
51 behavior for Mg^{2+} as an activator. Similar $K_{(A)}$ values for Mg^{2+} in the presence of
52
53 cAMP/cGMP were found. Classically, Mg^{2+} -as cofactor maximally stimulated PDE
54
55 from rat brain (53) and bovine retina (54,55) whereas Mn^{2+} and Co^{2+} only partially
56
57
58
59
60

1
2
3 enhanced PDE. Our results indicate that the PDE1A from PM-BTSM showed kinetic
4 parameters for the Mg^{2+} similar to others membrane bound PDEs (55).

5
6
7 PDE1s contain two Ca^{2+} /CaM binding domains required for full activation. The CaM
8 activation of the PDE1A from PM-BTSM was 2.2 fold (cAMP) and 1.8 times for
9 cGMP. Moreover, this PDE1A displayed a high affinity for CaM $K_{(CaM)}$ which are
10 closed to reported for the recombinant PDE1A2 (45).

11
12
13
14
15
16 One valuable tool in this work was the inhibitory effect of vinpocetine. Thus, the
17 vinpocetine displayed similar IC_{50} around 4.6-4.9 μM , independently of the cyclic
18 nucleotides. Vinpocetine is a selective PDE1 inhibitor, being a specific
19 pharmacological tool for PDE1 studies (51, 56, 57). Several PDE-1 displayed IC_{50} for
20 vinpocetine (from 8 to 50 μM) (30). Interestingly, the IC_{50} values here described for
21 vinpocetine are lower than the previously reported.

22
23
24
25
26
27
28
29
30 PDE1A family are involved in different biological processes (56,57) at the regulation
31 of vascular smooth muscle contraction (58) and heart remodeling (59) and plays a role
32 in function of the sperm (42,43). The function of the PDE1A from BTSM has to be
33 correlated to the regulation of cyclic nucleotides levels in ASM. In this sense, our
34 experimental findings supports a model, which is illustrated in Figure 7, where an
35 original signal transducing cascade integrates by a M_2AChR , directly coupled to a
36 PDE1A anchors at sarcolemma of ASM is proposed.

37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
This PDE1A might participate in the regulation of cyclic nucleotides levels at the sub-
plasmalemmal space in ASM. Thus, muscarinic antagonist drugs acting as “inverse
agonists” on M_2AChR leading to the inhibition of this PDE1A increasing the cyclic
nucleotide (cAMP, cGMP) content producing a profound relaxation of ASM, which is
important in asthma. The relevant role of M_2AChR on the action of muscarinic
antagonists is supported by the recent findings indicating that muscarinic antagonist

1
2
3 drug as tiotropium bromide (which selectively antagonizes the M₃AChR subtype) in
4
5 Ovalbumin-induced chronic asthma in mice (OVA) models, was able to inhibit the
6
7 expression of the M₃AChR and increased the M₂AChR (60). It can be hypothesized
8
9 that the muscarinic antagonist induces the M₂AChR expression and at the same time
10
11 acting on M₂AChR can inhibit the PDE1A here described. Both synergistic effects
12
13 can explained the powerful relaxation and beneficial therapeutic effects of these drugs
14
15 on asthma patients.
16
17

18
19 This hypothesis has to be demonstrated in biomodels such as the OVA-induced
20
21 asthma rats. In this sense, the future development of new drugs as compounds
22
23 derivate from vinpocetine, that selective inhibit this novel PDE1A, which might be a
24
25 promising pharmacological approach for the treatment of asthma or COPD.
26
27

28 **Conclusions.**

29
30 The cyclic nucleotides (cAMP and cGMP) levels in bovine tracheal smooth
31
32 muscle (BTSM) strips are modified in the presence of muscarinic antagonists. These
33
34 effects are mimicked by vinpocetine, a PDE1 inhibitor, suggesting that a PDE1 is
35
36 involved in the effects of muscarinic antagonists on BTSM strips. A PDE1 activity
37
38 which was inhibited by vinpocetine, was located in enriched plasma membrane (PM)
39
40 fractions from BSTM. These PM fractions exhibited only two muscarinic receptor
41
42 sub-types identified as M₂ and M₃AChRs. This PDE1 activity in these PM fractions
43
44 was strongly inhibited by muscarinic antagonists such as methoctramine relevant to
45
46 an M₂AChR. The inhibition was less strong for 4-DAMP, related to M₃AChRs
47
48 suggesting that an M₂AChR is involved in this biological effect. The membrane-
49
50 bound PDE1 was removed from these PM fractions, using a hypotonic extraction and
51
52 purified using two chromatography columns, an anion exchange (Q-sepharose)
53
54 followed by a calmodulin-agarose (CaM) affinity column. The PDE1 activity was
55
56
57
58
59
60

1
2
3 purified 38 times, yielding two bands in PAGE-SDS at 56 and 58 kDa. The 58 kDa
4
5 band was identified as the PDE1A isoenzyme using Western blotting analysis. This
6
7 isolated PDE1A exhibited inhibition by vinpocetine and activation by CaM.
8

9
10 This PDE1A activity assayed with [³H]cGMP and [³H]cAMP exhibited the following
11
12 kinetic parameters: the *K_m* for cAMP was 8.4 μM and for cGMP was 6.1 μM. The
13
14 *V_{max}* ratio was 1.5 for cAMP/cGMP. Vinpocetine showed similar *IC₅₀* (4.9 and 4.6
15
16 μM) for cAMP and cGMP respectively. CaM stimulated this PDE1A activity
17
18 exhibiting similar *K_(CaM)*, in the nM range for both cyclic nucleotides. The co-factor
19
20 Mg²⁺ showed similar values for both cyclic nucleotides with a *K_(A)* of 0.32 for cAMP
21
22 and 0.24 mM for cGMP. The original finding is the identification of a vinpocetine-
23
24 inhibited, atropine-inhibited and CaM-dependent plasma membrane-bound PDE1A,
25
26 which is linked to M₂AChR possibly by direct interaction between M₂AChR
27
28 intracellular loops with this PDE1A, which are support by the experimental data using
29
30 muscarinic antagonists. This is the first report of the presence of a membrane-bound
31
32 PDE1A at BTSM. Furthermore, a novel signal-transducing cascade with an M₂AChR
33
34 linked to this PDE1A, at the sarcolemma of ASM is proposed (Figure 7). It is possible
35
36 that this PDE1A participates in the regulation of cyclic nucleotide levels at the sub-
37
38 plasmalemmal space in ASM. Muscarinic antagonist drugs, acting as “inverse
39
40 agonists” on M₂AChR, leads to the inhibition of this PDE1A, increasing
41
42 simultaneously the cyclic nucleotide content of both cAMP and cGMP, with the
43
44 concomitant production of a profound ASM relaxation.
45
46
47

48
49 The future development of new drugs that selectively inhibit this novel PDE1A might
50
51 be a promising pharmacological approach for the treatment of asthma or COPD.
52
53
54
55
56
57
58
59
60

Abbreviations.

ASM, Airway smooth muscle; BTSM, Bovine Tracheal Smooth Muscle; Benzamidine, amidinobenzene hydrochloride; CaM, calmodulin; CCh, carbamylcholine; cAMP, cyclic adenosine 3', 5'-monophosphate; cGMP, cyclic guanosine 3',5'- monophosphate; 4-DAMP, 4-diphenylacetoxy-N-methylpiperidine; DTT, 1,4-dithiothreitol; PDE1A, phosphodiesterase 1A; PDE1B, phosphodiesterase tipo 1B; PDE1C, phosphodiesterase tipo 1C; PMSF: phenylmethylsulphonylfluoride; IBMX, isobutyl-methylxanthine; GPCR, G protein-coupled receptors; mAChR or MAChR, muscarinic acetylcholine receptor; M₂AChR, M₂ muscarinic receptor; M₃AChR, M₃ muscarinic receptor; NO-sGC, NO sensitive soluble guanylyl cyclase; NPR-GC, Natriuretic Peptides Receptor guanylyl cyclase; TCA , Trichloroacetic acid; Vinpocetine, (3 α , 16 β)-eburnamenine-14-carboxylic ethyl ester acid,.

Acknowledgments section.

This work was supported by grants from CDCH-UCV # PG 09-7772-2009/1(MJA) and CDCH-UCV # PG-09-7401-2008/2 (RGA) and CDCH-UCV # PI-09-7726.2009/2 (ILB). The authors thank Dr Coral Wynter for revision of the English version of this manuscript.

Declaration of Interest. The authors report no declarations of interest.

References.

- 1.- Van der Velden VH, Hulsmann AR. Autonomic innervation of human airways: structure, function, and pathophysiology in asthma. *Neuroimmunomodulation* (1999), 6, 145-59.
- 2.- Belmonte KE.. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. *Proc Am Thor Soc* (2005), 2, 297-304.
- 3.- Gosens R, Zaagsma J, Meurs H, Halayko AJ. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. *Resp Res* (2006), 7, 73-86.
- 4.- Challiss RA, Adams D, Mistry R, Boyle JP. Second messenger and ionic modulation of agonist-stimulated phosphoinositide turnover in airway smooth muscle. *Biochem Soc Trans* (1993), 21, 1138-45.
- 5.- Oldhman WM, Hamm HE. Heterotrimeric G protein activation by G-protein-coupled receptors. *Nat Rev Mol Cell Biol* (2008), 9, 60-71.
- 6.- Kotenis E, Zeng FY, Wess J. Structure-function of muscarinic receptors and their associated G proteins. *Life Sci* (1999), 64, 335-62.
- 7.- Maeda A, Kubo T, Mishina M, Numa S. Tissue distribution of mRNAs encoding muscarinic acetylcholine receptor subtypes. *FEBS Lett* (1998), 239, 339-42.
- 8.- Eglen RM, Hedge SS, Watson N. Muscarinic receptor subtypes and smooth muscle function. *Pharmacol Rev* (1996), 48, 531-65.
- 9.- Roffel AF, Elzinga CRS, Van Amsterdam RGM, De Zeueuw RA, Zaagsma J. Muscarinic receptors in bovine tracheal smooth muscle: Discrepancies between binding and function. *Eur J Pharmacol* (1988), 153, 73-82.
- 10.- Misle AJ, Bécemberg IL, Alfonzo RG, Alfonzo MJ. Methoctramine binding sites sensitive to alkylation on muscarinic receptors from tracheal smooth muscle. *Biochem Pharmacol* (1994), 48, 191-95.

- 1
2
3 11.- Hagiwara M, Endo T, Hidaka H. Effects of vinpocetine on cyclic nucleotide
4 metabolism in vascular smooth muscle. *Biochem. Pharmacol* (1984), 33, 453-57.
5
6
7 12.- Guerra de González L, González de Alfonzo R, Lippo de Bécemberg I, Alfonzo
8 MJ.. Cyclic nucleotide-dependent phosphodiesterases (PDE1) inhibition by
9 muscarinic antagonists in bovine tracheal smooth muscle. *Biochem Pharmacol* (2004),
10 68, 651-58.
11
12 13.- Torphy TJ, Cieslinski LB.. Characterization and selective inhibition of cyclic
13 nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle. *Mol*
14 *Pharmacol* (1990), 37, 206-14.
15
16 14.- Shahid M, Van Amsterdam R, De Boer J, Berge RE, Nicholson CD, Zaagsma
17 J.. The presence of five cyclic nucleotide phosphodiesterase isoenzyme activities in
18 bovine tracheal smooth muscle and functional effects of selective inhibitors. *Br J*
19 *Pharmacol*(1991), 104, 471-77.
20
21 15.- Beavo JA.. Multiple Isozymes of Cyclic Nucleotide Phosphodiesterases. *Adv*
22 *Second Messengers Phosphoprot Res* (1998), 22, 1-38.
23
24 16.- Beavo JA. Cyclic nucleotide phosphodiesterases: Functional implications of
25 multiple isoforms. *Physiol Rev* (1995), 75, 725-48.
26
27 17.- Sonnenburg, WK, Seger D, Kwak KS, Huang J, Charbonneau H, Beavo JA..
28 Identification of inhibitory and calmodulin-binding domains of the PDE1A1 and
29 PDE1A2 calmodulin-stimulated cyclic nucleotide phosphodiesterases. *J Biol Chem*
30 (1995), 270, 30989-31000.
31
32 18.- Guerra de González L, Misle A, Pacheco G, Napoleón de Herrera V, González de
33 Alfonzo R, Lippo de Bécemberg I, Alfonzo MJ. Effects of 1H-[1, 2, 4]-oxadiazolo
34 [4, 3-a] quinoxalin-1-one (ODQ) and N-omega (6)-nitro-L-arginine methyl ester
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(NAME) on cyclic GMP levels during muscarinic activation of tracheal smooth muscle. *Biochem Pharmac* (1999), 58, 563-69.

19.- Lippo de Bécemberg I, Correa de Adjounian MF, Peña de Aguilar E, González de Alfonzo R, Alfonzo MJ. G-protein-sensitive guanylyl cyclase activity associated with plasma membranes. *Arch Biochem Biophys* (1995), 324, 209-15.

20.- González de Alfonzo R, Bécemberg IL, Alfonzo MJ. A Ca^{2+} /CaM dependent protein kinase associated with Ca^{2+} transport in sarco(endo)plasmic vesicles from tracheal smooth muscle. *Life Sci* (1996), 58, 18-24.

21.- Gillespie PG, Beavo JA. Characterization of a bovine cone photoreceptor phosphodiesterase purified by cyclic GMP-sepharose chromatography. *J Biol Chem* (1988), 263, 8133-41.

22.- Sharma R, Wang T, Wirch E, Wang J. Purification and properties of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase. *J Biol Chem* (1980), 255, 5916-23.

23.- Benaim G, Zurini M, Carafoli E. Different conformational status of the purified Ca^{2+} -ATPase of the erythrocyte plasma membrane revealed by controlled trypsin proteolysis. *J. Biol. Chem* (1984), 259, 8471-77.

24.- Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature (Lond)* (1970), 227, 680-85.

25.- Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. *Proc Natl Acad Sci (USA)* (1979), 76, 4350-54.

26.- Bensadoun A, Weinstein D. Assay of proteins in the presence of interfering materials. *Anal Biochem* (1976), 70, 241-50.

27.- Perez JF, Sanderson MJ. The Frequency of Calcium Oscillations Induced by 5-

1
2
3 HT, ACH, and KCl Determine the Contraction of Smooth Muscle Cells of
4
5 Intrapulmonary Bronchioles. *J Gen Physiol* (2005), 125, 535-53.

6
7 28.- Pacheco G, Bécemberg IL, Alfonzo RG, Alfonzo MJ. Biochemical
8
9 characterization of a V-ATPase of tracheal smooth muscle plasma membranas.
10
11 *Biochim et Biophys Acta* (1996), 1282, 182-92.

12
13
14 29.- Kamm K, Stull J. Regulation of smooth muscle contractile elements by second
15
16 messengers. *Ann Rev Physiol* (1989), 51, 299-313.

17
18 30.- Beavo J, Houslay MD. *Cyclic Nucleotide Phosphodiesterases: Structure,*
19
20 *Function, Regulation, and Drug Action*, Chichester, United Kingdom: John Wiley &
21
22 Sons, (1990), vol. 2, 19-46.

23
24 31.- Michel AD, Whiting RL. Methoctramine reveals heterogeneity of M2 muscarinic
25
26 receptors in longitudinal ileal smooth muscle membranes. *Eur J Pharmacol* (1988),
27
28 145, 305-11.

29
30 32.- Michel AD, Stefanich E, Whiting RL. Direct labeling of rat M3-muscarinic
31
32 receptors by [³H]-4DAMP. *Eur J Pharmacol* (1989), 166, 459-66.

33
34 33.- Sankary RM, Jones CA, Madison JM, Brown JK. Muscarinic cholinergic
35
36 inhibition of cyclic AMP accumulation in airway smooth muscle. Role of a pertussis
37
38 toxin-sensitive protein. *Am Rev Respir Dis* (1988), 138, 145-50.

39
40 34.- Zhou XB, Wulfen I, Lutz S, Utku E, Sausbier U, Ruth P, Wieland T, Korth M.
41
42 M2 Muscarinic Receptors Induce Airway Smooth Muscle Activation via a Dual, G
43
44 $\beta\gamma$ -mediated Inhibition of Large Conductance Ca^{2+} -activated K Channel Activity. *J*
45
46 *Biol Chem* (2008), 283, 21036-44.

47
48 35.- Nakahara T, Yunoki M, Mitani A, Sakamoto K, Ishii K. Stimulation of
49
50 muscarinic M₂ receptors inhibits atrial natriuretic peptide-mediated relaxation in
51
52
53
54
55
56
57
58
59
60

1
2
3 bovine tracheal smooth muscle. *Naunyn Schmiedebergs Arch Pharmacol* (2002), 366,
4
5 376-79.

6
7 36.- Alfonzo MJ, Placeres-Uray F, Hassan-Soto W, Borges A, Gonzalez de Alfonzo
8
9 R, Lippo de Becemberg I. Two Guanylylcyclases Regulated the Muscarinic
10
11 Activation of Airway Smooth Muscle. In: Sugi H, ed. *Current Basic and Pathological*
12
13 *approaches to the function of muscle cells and tissues-From molecules to humans.*
14
15 Croatia: InTech, (2012), 113-32.

16
17 37.- Uray FP, de Alfonzo RG, de Becemberg IL, Alfonzo MJ. Muscarinic agonists
18
19 acting through M2 acetylcholine receptors stimulate the migration of an NO-sensitive
20
21 guanylyl cyclase to the plasma membrane of bovine tracheal smooth muscle. *J Recept*
22
23 *Signal Transduct Res* (2010), 30,10-23.

24
25 38.- Kan W, Adjobo-Hermans M, Burroughs M, Faibis G, Malik S, Tall G, Smrcka
26
27 A. M3 Muscarinic Receptor interaction with Phospholipase C β 3 determines its
28
29 signaling efficiency. *J Biol Chem* (2014), 289, 11206-18.

30
31 39.- Artemyev NO, Surendran R, Lee JC, Hamm HE. Subunit structure of rod cGMP-
32
33 phosphodiesterase. *J Biol Chem* (1966), 271, 25382-388.

34
35 40.- Baehr W, Devlin MJ, Applebury ML. Isolation and characterization of cGMP
36
37 phosphodiesterase from bovine rod outer segments. *J Biol Chem* (1979), 254, 11669-
38
39 677.

40
41 41.- Anant JS, Ong OC, Xie HY, Clarke S, O'Brien PJ, Fung BK. In vivo differential
42
43 prenylation of retinal cyclic GMP phosphodiesterase catalytic subunits. *J Biol Chem*
44
45 (1992), 267, 687-90.

46
47 42.- Chaudhry PS, Casillas ER. Calmodulin-stimulated cyclic nucleotide
48
49 phosphodiesterases in plasma membranes of bovine epididymal spermatozoa. *Arch*
50
51 *Biochem Biophys* (1988), 262, 439-44.

- 1
2
3 43.- Lefièvre L, Lamirande E, Gagnon C. Presence of Cyclic Nucleotide
4 Phosphodiesterases PDE1A, existing as a stable complex with Calmodulin, and
5 PDE3A in Human Spermatozoa. *Biol of Reprod* (2002), 67, 423-30.
6
7
8
9
10 44.- Snyder PB, Florio VA, Ferguson K, Loughney K. Isolation, expression and
11 analysis of splice variants of a human Ca²⁺/calmodulin stimulated phosphodiesterase
12 (PDE1A). *Cell Signal* (1999), 11, 535-44.
13
14
15
16 45.- Rybalkin S, Yan C, Bornfeldt K, Beavo JA. Cyclic GMP Phospho-diesterases
17 and Regulation of Smooth Muscle Function. *Circ Res* (2003), 93, 280-91.
18
19
20
21 46.- Vasta V, Sonnenburg WK, Yan C, Soderling SH, Shimizu-Albergine M, Beavo
22 JA. Identification of a New Variant of PDE1A Calmodulin-Stimulated Cyclic
23 Nucleotide Phosphodiesterase Expressed in Mouse Sperm. *Biology of Reproduction*
24 (2005), 73, 598-609.
25
26
27
28
29 47.- Michibata H, Yanaka N, Kanoh Y, Okumura K, Omori K. Human
30 Ca²⁺/calmodulin-dependent phosphodiesterase PDE1A: Novel splice variants, their
31 specific expression, genomic organization, and chromosomal localization. *Biochim*
32 *Biophys Acta* (2001), 1517, 278-87.
33
34
35
36
37
38 48.- Fidock M, Millar M, Lanfear J. Isolation and differential tissue distribution of
39 two human cDNAs encoding PDE-1 splice variants. *Cellular Signal* (2002), 14, 53-
40 60.
41
42
43
44
45 49.- Omori K, Kotera J. Overview of PDEs and their regulation. *Circ Res* (2007), 100,
46 309-27.
47
48
49
50 50.- Bender A, Beavo JA. Cyclic nucleotide phosphodiesterases: Molecular regulation
51 to clinical use. *Pharmacol Rev* (2006), 58, 488-520.
52
53
54 51.- Keravis T, Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) isozymes as
55 targets of the intracellular signaling network: benefits of PDE inhibitors in various
56
57
58
59
60

1
2
3 diseases and perspectives for future therapeutic developments. Review. *British of*
4
5 *Pharmacol* (2012), 165, 1288-1305.

6
7 52.- Wasco WM, Kincaid RL, Orr GA. Identification and characterization of
8
9 calmodulin-binding proteins in mammalian sperm flagella. *J Biol Chem* (1989), 264,
10
11 5104-11.

12
13 53.- Cheung WY. Properties of 3' 5'-nucleotide phosphodiesterase from rat brain.
14
15 *Biochemistry* (1967), 6, 1079-87.

16
17 54.- Chader G, Johnson M, Fletcher R, Bensinger R. Cyclic nucleotide
18
19 phosphodiesterase of the bovine retina: Activity, subcellular distribution and kinetics
20
21 parameters. *J Neurochem* (1974), 22, 93-9.

22
23 55.- Srivastava D, Fox DA, Hurwitz L. Effects of magnesium on cyclic GMP
24
25 hydrolysis by the bovine retinal rod cyclic GMP phosphodiesterase. *Biochem J*
26
27 (1995), 308, 653-58.

28
29 56.- Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target
30
31 for the development of specific therapeutic agents. *Pharmacol & Therap* (2006), 109,
32
33 266-398.

34
35 57.- Jeon YH, Heo YS, Kim CM, Hyun YL, Lee TG, Ro S, Cho JM.
36
37 Phosphodiesterase: overview of protein structures, potential therapeutic applications
38
39 and recent progress in drug development. Review. *CMLS, Cell Mol Life Sci* (2005),
40
41 62, 1198-1220.

42
43 58.- Chain S, Yan C. PDE1 isozymes, key regulators of pathological vascular
44
45 remodeling. *Curr Opin Pharmacol* (2011), 11, 720-24.

46
47 59.- Miller C, Cai Y, Oikawa M, Thomas T, Dostmann W, Zaccolo M, Fujiwara K,
48
49 Yan C. Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast
50
51

1
2
3 activation and extracellular matrix remodeling in the heart. *Basic Res Cardiol* (2011),
4
5 106,1023-39.
6

7
8 60.- Kang JY, Rhee CK, Kim JS, Park CK, Kim SJ, Lee SH, Yoon HK, Kwon SS,
9
10 Kim YK, Lee SY. Effect of tiotropium bromide on airway remodeling in a chronic
11
12 asthma model. *Ann Allergy Asthma Immunol* (2012), 109, 29-35.
13

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review Only

Figure 1.




Figure 1. The time course of cyclic nucleotides levels at BTSM strips during KCl induced contraction. Several BTSM strips (10 x 2 mm) were placed into a specially designed multi-organ chamber (400 mL) of KRB at 37°C as described in Methods. These BTSM strips were equilibrated during 30 min. Later, atropine (1×10^{-5} M) was added. After 15 min, KCl concentration was rise to 60 mM to induce BTSM depolarization. Each 20 s, individual strips were removed and placed into liquid nitrogen and the cyclic nucleotide extraction and determination were performed as described in Methods. Each value is the mean \pm SE of 5 different BTSM strips. Basal cGMP at OT (Δ); Basal cAMP OT (\blacktriangle), Basal cGMP (\circ); Basal cAMP (\square); cGMP plus KCl (\bullet); cAMP plus KCl (\blacksquare).

44x36mm (300 x 300 DPI)

Figure 2




Figure 2. Effect of muscarinic antagonists on the PDE1 activity at plasma membranes fraction from BTSM. PM-BTSM (20-30 μ g) fractions were incubated with [3 H] cGMP as PDE substrate as described in Methods. A dose titration curves of muscarinic antagonists such as methoctramine (\square) and 4-DAMP (\blacktriangle) were performed. The inhibitory concentration IC₅₀ was estimated as described in Methods. Data are the mean \pm SE of three (3) different PM preparations.
44x46mm (300 x 300 DPI)

Figure 3A and 3B.




Figure 3A. Typical protein elution profile from Q-sepharose column.

HE was applied to a Q-sepharose and washed with buffer 1 plus 50 mM NaCl and eluted with a linear gradient of NaCl (0.4 - 1.0 M) as shown. Protein fractions were grouped as "Pool I". Inset: The vinpocetine and CaM effects on the PDE activity assayed at "Pool I" (20-30 μ g protein) and [3 H] cGMP with Ca $^{2+}$ /CaM (1 mM/5 nM) and Vinpocetine (20 μ M). Data are the mean \pm SE of five preparations assayed by duplicate.

* $p < 0.05$; Basal PDE1 vs Ca $^{2+}$ /CaMPDE1. ** $p < 0.001$; Basal PDE1 vs ViPDE1.

Figure 3B. Typical protein profile from (CaM-agarose) affinity column.

The Pool-I was placed on CaM-agarose equilibrated with buffer 1 plus 100 μ M Ca $^{2+}$ and 5 mM DTT and incubated overnight at 4°C. Later, the column was washed with buffer 1 without Ca $^{2+}$ or EGTA. Later, the CaM-agarose was eluted with buffer 1 containing 2 mM EGTA and protein fractions were grouped into a "Pool II", concentrated using a Millipore YM-10. Inset.- The inhibitory effect of Vinpocetine and stimulation by CaM at "Pool II". The PDE activity was determined using "Pool II" (10-20 μ g protein) and [3 H]cGMP with Ca $^{2+}$ /CaM (1 mM/5 nM) and Vinpocetine (20 μ M). Data are the mean \pm SE of five (5) preparations assayed in duplicate. * $p < 0.05$; Basal PDE vs Ca $^{2+}$ /CaMPDE. ** $p < 0.001$; Basal PDE vs ViPDE1.

45x31mm (300 x 300 DPI)

Figure 4A and 4B.




Figure 4A. Kinetic behavior of PDE1A in the presence of cAMP/cGMP. The "Pool-I" (30-40 μ g of protein) was incubated at 30° C for 15 min, and increasing concentrations of cAMP(□)/cGMP (■) as described in Methods. The PDE 1 activity was expressed as pmoles of cyclic nucleotide hydrolyzed/min/mg protein. The K_m and V_{max} were determined as described in Methods. Data represent the mean \pm SE of three (3) different preparations.

Figure 4B. The magnesium ($MgCl_2$) titration on the PDE1A activity. The "Pool-I" (30-40 μ g of protein) was incubated with increasing concentrations of $MgCl_2$ in the presence of cAMP(□)/cGMP (■) as described in Methods. The kinetic parameters ($K(A)$ and V_{max}) were determined as described in Methods. Data represent the mean \pm SE of three (3) different preparations.

45x32mm (300 x 300 DPI)

Figure 5A and 5B.




Figure 5A. Kinetic behavior of PDE1A in the presence of Vinpocetine.

The "Pool-I" (30-40 μ g of protein) was incubated with increasing doses of vinpocetine in the presence of cAMP(\square)/cGMP (\blacksquare) as described in Methods. The K_m and V_{max} were determined as described in Methods.

Data represent the mean \pm SE of three (3) different preparations.

Figure 5B. The effect of calmodulin on the PDE1A activity.

The "Pool-I" (30-40 μ g of protein) was incubated with increasing amounts of CaM in the presence of cAMP(\square)/cGMP (\blacksquare) as described in Methods. The kinetic parameters (K_m and V_{max}) were determined as described in Methods. Data represent the mean \pm SE of three (3) different preparations.

45x32mm (300 x 300 DPI)




Figure 6. SDS-PAGE and Western blots from BTSM containing active PDE1. Membrane proteins (5-50 μ g) were analyzed on SDS-PAGE 10% gels. The samples were: Lane 1: PM (50 μ g). Lane 2: HE (50 μ g). Lane 3: "Pool I", (15 μ g). Lane 4: "Pool II", (5 μ g). Lane 5: Protein standards (Mw) from 28.3 to 132 kDa. Inset.-PDE-1A: Western blots for the PDE1 purified from the BTSM. Protein samples were run on SDS-PAGE 10% gels and transferred to PDVF membranes, which were incubated with specific antibodies against the PDE1A isoform as described in Methods. Lane 1: PM (50 μ g). Lane 2: HE (50 μ g). Lane 3: "Pool I", (15 μ g). Lane 4: "Pool II", (5 μ g).

52x51mm (300 x 300 DPI)

Figure 7

Figure 7




Figure 7. A model of a novel transducing cascade associated with muscarinic receptors (M_2AChRs) and the PDE1A.

This model of a signal transducing pathway of the airway smooth muscle (ASM) proposes that muscarinic agents (antagonists) acting as "inverse agonists" bind to the M_2AChR located to ASM sarcolemma, which induces the inhibition of a plasma membrane-bound PDE1A, which is vinpocetine-inhibited and CaM stimulated enzyme. This last PDE1A inhibition can increase the cGMP/cAMP intracellular levels, inducing ASM relaxation.

45x47mm (300 x 300 DPI)

Table 1. Subcellular location of the vinpocetine-inhibited PDE1 (ViPDE).

Fractions	cAMP	cGMP
E	4.51 ± 0.22	4.02 ± 0.43
N	1.53 ± 0.15	1.50 ± 0.18
M	4.58 ± 0.27	4.17 ± 0.10
S	1.21 ± 0.14	1.02 ± 0.11
P	5.24 ± 0.23	5.02 ± 0.18
PM	7.89 ± 0.42	7.12 ± 0.31

The vinpocetine-inhibited PDE1 (ViPDE) as pmoles of cyclic nucleotides hydrolyzed/min/mg protein was evaluated during the subcellular fractionation procedure, which was estimated as the Basal PDE activity minus the PDE activity in the presence of vinpocetine. The enzyme activity was determined using [³H]cGMP and [³H]cAMP as substrates in the presence or absence of 20μM vinpocetine as described in Methods. The samples evaluated were: E: crude extract, N: Nuclear fraction, S: Cytosol, P: Microsomal fraction and PM: plasma membranes fraction. Data are the mean ± SE of ViPDE activity assayed in duplicate from five (5) different subcellular preparations of BTSM.

Table 2. Evaluation of the ViPDE and atropine sensitive activities during the hypotonic extraction of PM from BTSM.

Fractions	ViPDE activity	Atropine sensitive PDE
PM	7.16 ± 1.22	8.12 ± 1.87
HE	15.32 ± 0.22	1.02 ± 0.18
SED	1.58 ± 0.29	1.24 ± 0.21

The vinpocetine-inhibited PDE1 (ViPDE) and atropine-sensitive PDE were evaluated during the extraction procedure. The ViPDE and atropine sensitive PDE were estimated as the Basal PDE activity minus the PDE activity in the presence of either 20 µM vinpocetine or 1µM atropine. The enzyme activity was determined using [³H]cGMP as substrate as described in Methods. The samples evaluated were: PM: plasma membranes fraction, HE: Hypotonic extract, SED: Sediment. Data are the mean ± SE of PDE activity assayed in duplicate from five (5) different PM extraction preparations.

Table 3. Purification and activity of the vinpocetine-inhibited PDE1 from bovine tracheal smooth muscle.

Fractions	Protein (mg/mL)	Vol (mL)	Total Protein (mg)	S.A. pmol/min/mg	Total Activity (pmol/min)	Purification Factor
E	10.2 ± 0.22	900	9,180 ± 198	4.0 ± 0.2	36,720 ± 790	1.0
PM	7.0 ± 0.15	50	350 ± 18	7.2 ± 0.3	2,520 ± 120	1.8
HE	0.18±0.02	900	162 ± 10	14.1 ± 0.4	2,268 ± 90	3.5
Pool I	5.2 ± 0.4	2.0	10.4 ± 0.8	72.1 ± 6.2	750 ± 40	18.0
Pool II	1.0 ± 0.1	0.5	0.5 ± 0.04	152.1± 8.2	76 ± 4	38.0

The vinpocetine-inhibited PDE1 (ViPDE) activity was evaluated during the purification procedure. ViPDE was estimated as the subtraction of Basal PDE activity minus the PDE activity in the presence of vinpocetine. Protein content was measured as described in Methods. The enzyme activity was determined using [³H]cGMP as substrate in the presence or absence of 20µM vinpocetine as described in Methods. The samples evaluated were: E: crude extract, PM: plasma membranes fraction, HE: hypotonic extract, Pool I: Active fractions obtained from Q-sepharose column, Pool II: Active fractions from CaM-agarose column. The purification factor was estimated as the ratio of the specific activity (S.A.) of each fraction divided into the specific activity of E fraction. Data are the mean ± SE of ViPDE activity assayed in duplicate from five (5) different subcellular preparations of BTSM.